The catalog of anti-idiotypic reagents has been expanded to include the therapeutic tar­gets adalimumab, ipilimumab, and rituximab. These anti-ID Affimer® reagents have been developed in collaboration with leading CROs and pharmaceutical companies. They offer a number of benefits, including: highly specific and sensitive rec­ognition of your therapeutic antibody with a generic detection system to overcome the need for bridging assays and simplify assay set-up, low matrix effect to ensure assay performance within a range of complex samples, and batch-to-batch consistency assuring the security of supply. The company is expanding its range of anti-ID reagents to include more therapeutic antibody targets and Affimer reagent binding modes. Lastly a custom anti-ID development service offers rapid development of reagents, with no affinity maturation needed.